文献速递肿瘤 PET/CT

18F-ISO-1在乳腺癌中的摄取作为增殖状态标志物的临床研究

Breast Cancer 18F-ISO-1 Uptake as a Marker of Proliferation Status.
PubMed 文献 · J Nucl Med · 2019-12-13

该研究前瞻性纳入28例女性29个原发性浸润性乳腺癌,评估18F-ISO-1 PET/CT能否在体内测量肿瘤增殖状态。结果显示肿瘤SUVmax与Ki-67表达呈正相关(ρ=0.46,P=0.01,n=29),高Ki-67组SUVmax高于低Ki-67组(P=0.02),但肿瘤/正常组织比值和分布容积比与Ki-67无相关性。

要点

  • 18F-ISO-1 PET/CT SUVmax与乳腺癌Ki-67表达呈中度正相关。
  • 高Ki-67(≥20%)组SUVmax显著高于低Ki-67(<20%)组。
  • 肿瘤/正常组织比值和分布容积比与Ki-67无显著相关性。

核心结论

  • 18F-ISO-1在乳腺癌中的摄取与体外增殖检测(Ki-67)呈中度相关。

研究设计与样本

  • 前瞻性临床试验(NCT02284919)纳入28例女性29个原发性浸润性乳腺癌,2015年3月至2017年1月入组。
  • 每例注射278-527 MBq的18F-ISO-1,50-55分钟后行乳腺PET/CT显像。
  • 体内摄取以SUVmax和分布容积比定量,与体外Ki-67免疫组化比较。
  • 采用Wilcoxon秩和检验评估不同Ki-67阈值间的摄取差异,Spearman相关检验摄取与Ki-67的关联。

主要发现

  • 肿瘤SUVmax中位数2.0 g/mL(范围1.3-3.3 g/mL)。
  • 高Ki-67(≥20%)组SUVmax高于低Ki-67(<20%)组(P=0.02)。
  • SUVmax与Ki-67在所有乳腺癌亚型中呈正相关(ρ=0.46,P=0.01,n=29)。
  • 部分容积校正SUVmax与Ki-67在浸润性导管癌中呈正相关(ρ=0.51,P=0.02,n=21)。
  • 肿瘤/正常组织比值和肿瘤分布容积比与Ki-67无相关性(P>0.05)。

关键数值与推荐

  • Ki-67高表达阈值定义为≥20%,低表达定义为<20%。
  • SUVmax与Ki-67相关系数ρ=0.46,P=0.01,n=29。
  • 部分容积校正SUVmax与Ki-67在浸润性导管癌中相关系数ρ=0.51,P=0.02,n=21。

临床怎么用

  • 18F-ISO-1 PET/CT的SUVmax可作为乳腺癌增殖状态的体内评估指标。
  • SUVmax有助于区分高Ki-67(≥20%)与低Ki-67(<20%)的乳腺癌。
  • 肿瘤/正常组织比值和分布容积比不推荐用于评估增殖状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The σ2 receptor is a potential in vivo target for measuring proliferative status in cancer. The feasibility of using N-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-2-(2-18F-fluoroethoxy)-5-methylbenzamide (18F-ISO-1) to image solid tumors in lymphoma, breast cancer, and head and neck cancer has been previously established. Here, we report the results of the first dedicated clinical trial of 18F-ISO-1 in women with primary breast cancer. Our study objective was to determine whether 18F-ISO-1 PET could provide an in vivo measure of tumor proliferative status, and we hypothesized that uptake would correlate with a tissue-based assay of proliferation, namely Ki-67 expression. Methods: Twenty-eight women with 29 primary invasive breast cancers were prospectively enrolled in a clinical trial (NCT02284919) between March 2015 and January 2017. Each received an injection of 278-527 MBq of 18F-ISO-1 and then underwent PET/CT imaging of the breasts 50-55 min later. In vivo uptake of 18F-ISO-1 was quantitated by SUVmax and distribution volume ratios and was compared with ex vivo immunohistochemistry for Ki-67. Wilcoxon rank-sum tests assessed uptake differences across Ki-67 thresholds, and Spearman correlation tested associations between uptake and Ki-67. Results: Tumor SUVmax (median, 2.0 g/mL; range, 1.3-3.3 g/mL), partial-volume-corrected SUVmax, and SUV ratios were tested against Ki-67. Tumors stratified into the high-Ki-67 (≥20%) group had SUVmax greater than the low-Ki-67 (<20%) group (P = 0.02). SUVmax exhibited a positive correlation with Ki-67 across all breast cancer subtypes (ρ = 0.46, P = 0.01, n = 29). Partial-volume-corrected SUVmax was positively correlated with Ki-67 for invasive ductal carcinoma (ρ = 0.51, P = 0.02, n = 21). Tumor-to-normal-tissue ratios and tumor distribution volume ratio did not correlate with Ki-67 (P > 0.05). Conclusion:18F-ISO-1 uptake in breast cancer modestly correlates with an in vitro assay of proliferation.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. McDonald ES, Doot RK, Young AJ, et al. Breast Cancer 18F-ISO-1 Uptake as a Marker of Proliferation Status. J Nucl Med. 2019. PMID: 31836680. doi:10.2967/jnumed.119.232363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。